Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
29.05. | Tyra Biosciences, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
21.05. | Piper Sandler raises Tyra Biosciences stock target to $33 | 1 | Investing.com | ||
08.05. | Tyra Biosciences GAAP EPS of -$0.47 | 1 | Seeking Alpha | ||
08.05. | Tyra Biosciences files $500M mixed securities shelf | 4 | Seeking Alpha | ||
08.05. | Tyra Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
08.05. | Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights | 180 | PR Newswire | - BEACH301 study of TYRA-300 for Pediatric Achondroplasia (ACH) Open for Enrollment -
- Initiated patient dosing in SURF431 study of TYRA-430 for hepatocellular... ► Artikel lesen | |
TYRA BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
31.03. | H.C. Wainwright maintains $30 target on Tyra Biosciences stock | 1 | Investing.com | ||
27.03. | Tyra Biosciences GAAP EPS of -$0.43 | 1 | Seeking Alpha | ||
27.03. | Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights | 133 | PR Newswire | - Three INDs cleared by US FDA for TYRA's proprietary precision small molecules -
- TYRA-300 to be evaluated in three Phase 2 studies: SURF302 for Intermediate Risk... ► Artikel lesen | |
27.03. | Tyra Biosciences, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
18.02. | H.C. Wainwright maintains $30 target on Tyra Biosciences stock | 1 | Investing.com | ||
29.01. | Tyra Biosciences adds Adele Gulfo to board | 1 | Investing.com | ||
29.01. | Tyra Biosciences, Inc. - 8-K, Current Report | - | SEC Filings | ||
10.01. | Tyra Biosciences treibt klinische Studie für Blasenkrebsmedikament voran | 2 | Investing.com Deutsch | ||
10.01. | Tyra Biosciences advances bladder cancer drug trial | 1 | Investing.com | ||
10.01. | Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302) | 203 | PR Newswire | -TYRA appoints urologic oncologist, Erik Goluboff, M.D., as SVP, Clinical Development to lead NMIBC-
-First patient expected to be dosed in SURF302 in Q2 2025-
... ► Artikel lesen | |
07.11.24 | Tyra Biosciences Reports Third Quarter 2024 Financial Results and Highlights | 179 | PR Newswire | - Reported positive interim clinical proof-of-concept results for TYRA-300 in mUC from SURF301 Ph1/2 study -
- IND cleared for Phase 2 study of TYRA-300 in pediatric... ► Artikel lesen | |
28.10.24 | Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301) | 201 | PR Newswire | - TYRA-300 is the first oral FGFR-3 selective inhibitor to be well-tolerated in clinical studies -
- First child with achondroplasia expected to be dosed in Q1 2025... ► Artikel lesen | |
25.10.24 | Tyra Biosciences, Inc.: Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic ... | 197 | PR Newswire | - Encouraging preliminary anti-tumor activity observed in heavily pre-treated population -
- At = 90 mg QD, 6 out of 11 (54.5%) patients with FGFR3+ mUC achieved... ► Artikel lesen | |
10.09.24 | Tyra Biosciences Appoints Doug Warner, M.D., as Chief Medical Officer | 359 | PR Newswire | -Dr. Warner brings over twenty years of proven clinical development leadership to TYRA having successfully led global development and secured approvals for medicines across oncology and skeletal disease-
... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data | ||
CG ONCOLOGY | 25,950 | -0,46 % | CG Oncology Inc.: CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates | - Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal... ► Artikel lesen | |
QIAGEN | 41,000 | -0,56 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
LYELL IMMUNOPHARMA | 8,940 | -1,97 % | Lyell Immunopharma, Inc. - 8-K, Current Report | ||
SPRINGWORKS THERAPEUTICS | 46,990 | 0,00 % | SpringWorks Therapeutics, Inc. - 8-K, Current Report | ||
KYMERA THERAPEUTICS | 44,080 | -3,57 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
CLIMB BIO | 1,180 | -5,60 % | Climb Bio, Inc.: Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer | Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll... ► Artikel lesen | |
ADMA BIOLOGICS | 18,160 | -1,30 % | Will Strong Asceniv Sales Drive ADMA Biologics Further? | ||
ALLOGENE THERAPEUTICS | 1,180 | -1,67 % | Allogene Therapeutics, Inc. - 8-K, Current Report | ||
RECURSION PHARMACEUTICALS | 5,030 | -6,85 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
EVOTEC | 7,138 | -0,81 % | Aktienmarkt: Evotec-Aktie kann sich nicht behaupten (6,38 €) | An der deutschen Börse liegt das Wertpapier von Evotec aktuell im Minus. Das Wertpapier notiert zur Stunde bei 6,38 Euro. Am Aktienmarkt liegt die Aktie von Evotec gegenwärtig im Minus. Die Aktie verbilligte... ► Artikel lesen | |
BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
CARGO THERAPEUTICS | 4,190 | -0,71 % | Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 20,610 | -3,33 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |